

Supplementary table S1			
	CT-ILD (N=26)	CT-airway disease (N=5)	CT-others (N=5)
IL-18 (pg/ml)	721.0±481.4	541.7±310.4	1473.9±1654.3
Age (yr)	69.8±9.5	63.8±5.3	78.8±2.4
Female n (%)	21 (80.8)	5 (100)	3 (60)
Disease duration (yr)	15.7±11.3	18.4±9.9	16.0±9.6
CTD n (%)	2 (7.7)	0	0
Smoking history n (%)	8 (30.8)	1 (20)	2 (40)
Stage III or IV n (%)	18 (69.2)	4 (80)	4 (80)
Class 3 or 4 n (%)	5 (19.2)	1 (20)	3 (60)
DAS28_CRP	2.83±1.09	3.57±0.72	3.24±0.73
HAQ	1.13±0.86	0.98±0.28	1.68±0.4
TSS	159.3±140.3	163±151.3	176.1±119.7
Use of BIO n (%)	5 (19.2)	0	1 (20)
Use of MTX n (%)	15 (57.6)	4 (80)	4 (80)
Dose of MTX (mg/week)	3.2±3.2	5.2±3.9	8.4±8.2
Use of GCs n (%)	17 (65.4)	2 (40)	5 (100)
Dose of GCs (mg/day)	4.7±5.3	0.7±1.0	6.2±1.9
Anti-CCP positive n (%)	25 (96.1)	4 (80)	4 (80)
Anti-CCP titer (U/ml)	199.7±104.6	88.7±50.1	64.8±103.9
RF positive n (%)	23 (88.5)	4 (80)	3 (60)
RF titer (U/ml)	128.0±243.1	94.6±74.8	295.7±378.0
ANA positive (%)	7 (26.9)	1 (20)	1 (20)
KL-6 (U/ml)	471.3±326.8	302.4±141.3	455.8±245.2
MMP-3 (ng/ml)	210.3±183.9	263.4±114.5	182.9±104.0
LDH (IU/l)	217.7±43.9	198±24.1	285±20.6
CRP (mg/dl)	1.50±1.70	1.48±0.53	1.68±1.77
ESR (mm/1h)	36.3±27.0	40.2±12.1	50.6±28.1

Supplementary table S2			
	CT-NSIP (N=11)	CT-UIP (N=14)	CT-unclassifiable (N=1)
IL-18 (pg/ml)	723.8±327.4	758.8±553.0	161.2
Age (yr)	69.3±8.0	70.1±10.9	70
Female n (%)	8 (72.7)	12 (85.7)	1 (100)
Disease duration (yr)	16.0±12.2	15.4±10.9	15
CTD n (%)	10 (9.1)	9 (7.1)	0
Smoking history n (%)	5 (45.5)	3 (21.4)	0
Stage III or IV n (%)	7 (63.6)	11 (78.6)	0
Class 3 or 4 n (%)	2 (18.2)	3 (21.4)	0
DAS28_CRP	2.78±0.83	3.01±1.15	1.03
HAQ	0.95±0.69	1.36±0.90	0
TSS	119.9±108.0	204.4±145.7	20
Use of BIO n (%)	0	5 (35.7)	0
Use of MTX n (%)	6 (54.5)	8 (57.1)	1 (100)
Dose of MTX (mg/week)	2.9±3.0	3.1±3.2	8
Use of GCs n (%)	8 (72.7)	8 (57.1)	1 (100)
Dose of GCs (mg/day)	5.3±5.5	3.5±4.2	15
Anti-CCP positive n (%)	10 (90.9)	14 (100)	1 (100)
Anti-CCP titer (U/ml)	172.2±113.8	218.4±95.3	242
RF positive n (%)	8 (72.7)	14 (100)	1 (100)
RF titer (U/ml)	110.0±279.8	139.4±210.3	35.8
ANA positive (%)	1 (10)	5 (38.5)	1 (100)
KL-6 (U/ml)	357.7±142.1	570.3±401.5	334
MMP-3 (ng/ml)	237.0±168.0	201.6±195.7	90.8
LDH (IU/l)	237.1±45.0	208.4±39.1	173
CRP (mg/dl)	0.87±1.12	2.1±1.88	0
ESR (mm/1h)	25.9±22.2	46.5±26.8	2

Supplementary Figure1

RA-ILD patients (N=26)

